LB Pharmaceuticals Announces $100.0 Million Private Placement

Rhea-AI Summary

LB Pharmaceuticals (Nasdaq: LBRX) entered a securities purchase agreement to sell 3,306,571 shares of common stock and pre-funded warrants to purchase up to 1,417,107 shares at $21.17 per share (pre-funded warrant price $21.1699), anticipating approximately $100.0 million gross proceeds.

The private placement is expected to close on or about February 6, 2026, includes major institutional investors, and names Leerink Partners, Piper Sandler and Stifel as placement agents. Proceeds are intended to fund a Phase 2 trial of LB-102 in major depressive disorder and for working capital; resale registration rights were agreed with investors.

Positive

• Raised approximately $100.0 million in expected gross proceeds
• Financing includes participation from multiple institutional investors
• Net proceeds intended to fund a Phase 2 LB-102 trial for major depressive disorder
• Registration rights agreed to enable resale of purchased securities

Negative

• Potential issuance of up to 4,723,678 shares (shares plus pre-funded warrant shares) increasing outstanding share count
• Pre-funded warrants have a nominal $0.0001 exercise price, enabling near-zero-cost conversion to shares
• Securities are unregistered at issuance and resale is restricted pending a registration filing

Argus Feb 5 session

+12.71% close to close Open Argus

Details

News Market Reaction – LBRX

In the Feb 5 session, LBRX gained 12.71%, reflecting a significant positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock surged +12.7% in the session following this news. A strong positive reaction aligns with t...

Analysis

The stock surged +12.7% in the session following this news. A strong positive reaction aligns with the company raising $100.0 million in new capital at a price of $21.17 per share, above the 200-day MA of $18.10. Prior news showed mixed price responses to operational updates, so financing strength could be interpreted as validation of the development plan for LB‑102. Investors might still weigh potential dilution from the 3,306,571 shares and 1,417,107 pre-funded warrants against the benefit of funding a new Phase 2 trial.

Key Figures

Common shares sold: 3,306,571 shares Pre-funded warrants: 1,417,107 warrants Share purchase price: $21.17 per share +4 more

Common shares sold

3,306,571 shares

Shares of common stock in private placement

Pre-funded warrants

1,417,107 warrants

Pre-funded warrants to purchase common stock

Share purchase price

$21.17 per share

Purchase price for common stock in private placement

Warrant purchase price

$21.1699 per warrant

Purchase price for each pre-funded warrant

Warrant exercise price

$0.0001 per share

Exercise price for shares underlying pre-funded warrants

Gross proceeds

$100.0 million

Anticipated gross proceeds from private placement before expenses

Expected closing date

February 6, 2026

Target closing date for private placement

Historical Context

5 past events · Latest: Jan 26

5 events

1. Jan 26

   Clinical trial initiation

   24h Move

   -6.4%

   Started Phase 2 ILLUMINATE-1 trial of LB-102 in bipolar 1 depression.

2. Jan 21

   Executive appointment

   24h Move

   +0.7%

   Appointed experienced General Counsel to support CNS-focused strategy.

3. Jan 12

   Inducement equity grants

   24h Move

   +4.0%

   Granted stock options to two senior hires under Nasdaq inducement rule.

4. Jan 06

   Leadership hires

   24h Move

   -3.3%

   Added SVPs for Corporate Affairs and People & Culture to support LB-102.

5. Dec 10

   Inducement option grant

   24h Move

   -2.8%

   Granted 195,000-share stock option to new Chief Commercial Officer.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

private placement, pre-funded warrants, securities purchase agreement, registration rights agreement, +1 more

5 terms

private placement financial

"to a select group of institutional investors in a private placement."

A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.

pre-funded warrants financial

"and pre-funded warrants to purchase up to 1,417,107 shares of its common stock"

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

securities purchase agreement financial

"announced that it has entered into a securities purchase agreement to sell 3,306,571 shares"

A securities purchase agreement is a written contract between a buyer and a seller outlining the terms for buying or selling financial assets such as stocks or bonds. It specifies details like the price, quantity, and conditions of the transaction, similar to a shopping list with agreed-upon terms. For investors, it provides clarity and legal protection when transferring ownership of these financial instruments.

registration rights agreement regulatory

"entered into a registration rights agreement pursuant to which LB Pharmaceuticals has agreed"

A registration rights agreement is a contract that gives investors the option to have their ownership stakes officially registered with the government, making it easier to sell their shares later. This agreement matters because it provides investors with a clearer path to cash out their investments if they choose, offering more liquidity and confidence in their ability to sell their holdings when desired.

registration statement regulatory

"agreed to file a registration statement with the Securities and Exchange Commission"

A registration statement is a formal document that companies file with a government agency to offer new shares of stock to the public. It provides essential information about the company's finances, operations, and risks, helping investors make informed decisions. Think of it as a detailed product description that ensures transparency and trust before buying into a company.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, and other neuropsychiatric diseases, today announced that it has entered into a securities purchase agreement to sell 3,306,571 shares of its common stock and pre-funded warrants to purchase up to 1,417,107 shares of its common stock to a select group of institutional investors in a private placement. The purchase price of each share of common stock is $21.17. The purchase price of each pre-funded warrant is $21.1699, which represents the per share purchase price for the common stock less the $0.0001 per share exercise price for such pre-funded warrant. LB Pharmaceuticals anticipates the gross proceeds from the private placement to be approximately $100.0 million, before deducting any transaction-related expenses. The private placement is expected to close on or about February 6, 2026, subject to the satisfaction of customary closing conditions.

The financing includes participation from new and existing institutional investors, including Balyasny Asset Management L.P., Caligan Partners, Commodore Capital, Deep Track Capital, Nantahala Capital, Pivotal bioVenture Partners, Spruce Street Capital, TCGX, Trails Edge Capital Partners, and other investors.

Leerink Partners, Piper Sandler and Stifel acted as placement agents for the private placement.

LB Pharmaceuticals intends to use the net proceeds from the private placement to fund a Phase 2 trial for LB-102 as an adjunctive treatment for major depressive disorder, and for working capital and general corporate purposes.

The offer and sale of the securities to be sold in the private placement have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or any state or other applicable jurisdiction’s securities laws, and such securities may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and applicable state or other jurisdictions’ securities laws. Concurrently with entering into the securities purchase agreement, LB Pharmaceuticals and the investors entered into a registration rights agreement pursuant to which LB Pharmaceuticals has agreed to file a registration statement with the Securities and Exchange Commission registering the resale of the shares of common stock issued in the private placement, including the shares of common stock underlying the pre-funded warrants.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

About LB Pharmaceuticals

LB Pharmaceuticals is a late-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. The Company is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the Company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102, if approved, has the potential to become a mainstay of psychiatric practice by offering a balanced clinical activity and tolerability profile that provides a potentially attractive alternative to branded and generic therapeutics for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,” “predict,” “seek,” “should,” “target,” “will,” “would” or similar expressions are intended to identify forward-looking statements. All statements other than statements of historical facts contained in this press release are forward-looking statements. These forward-looking statements include, but are not limited to, statements concerning expected proceeds from the private placement, expected use of proceeds, and expected closing of the private placement. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among others: the Company’s limited operating history and historical losses; the Company’s ability to raise additional funding to complete the development and any commercialization of LB-102; the Company’s dependence on the success of its lead product candidate, LB-102; the Company’s ability to obtain regulatory approval of and successfully commercialize its product candidate; the late stages of clinical development of the Company’s lead product candidate, LB-102; any undesirable side effects or other properties of the Company’s product candidate; that the Company may be delayed in initiating, enrolling or completing any clinical trials; competition from third parties that are developing products for similar uses; the Company’s ability to obtain, maintain and protect its intellectual property; and the Company’s dependence on third parties in connection with manufacturing, clinical trials and preclinical studies. These and other risks are described more fully in the section titled “Risk Factors” in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2025 and its other documents to be subsequently filed with or furnished to the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Media & Investor Contact:
Ellen Rose
erose@lbpharma.us

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much cash will LBRX raise in the February 5, 2026 private placement?

LB Pharmaceuticals expects to raise approximately $100.0 million in gross proceeds. According to the company, this amount is before transaction expenses and is subject to customary closing conditions expected around February 6, 2026.

What securities did LBRX sell and at what price per share in the private placement?

LBRX sold 3,306,571 common shares and pre-funded warrants to purchase up to 1,417,107 shares. According to the company, the per-share price was $21.17 and each pre-funded warrant priced at $21.1699.

How will LBRX use the proceeds from the private placement?

The company intends to use net proceeds to fund a Phase 2 trial of LB-102 for major depressive disorder and for working capital. According to the company, these are the primary stated uses of funds.

When will the private placement for LBRX close and are there resale restrictions?

The private placement is expected to close on or about February 6, 2026, subject to closing conditions. According to the company, the securities were not registered at issuance and resale is restricted until a registration statement is filed.

Which institutional investors and placement agents participated in LBRX's financing?

Participating investors include names like Balyasny Asset Management and others; placement agents were Leerink Partners, Piper Sandler and Stifel. According to the company, both new and existing institutional investors joined the transaction.